




RealRate

PHARMACEUTICAL 2023

Lexicon Pharmaceuticals INC
Rank 255 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lexicon Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lexicon Pharmaceuticals INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Lexicon Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 240%, being 4.5% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	140,866
Cost of Goods Sold	0
Intangible Assets	44,543
Liabilities, Current	23,172
Liabilities, Non-Current	5,424
Other Assets	6,819
Other Compr. Net Income	-418
Other Expenses	2,780
Other Liabilities	48,579
Other Net Income	1,596
Other Revenues	139
Property and Equipment	2,071
Research and Development	52,816
Selling, General and Administrative Expense	48,083

Output Variable	Value in 1000 USD
Assets	194,299
Liabilities	77,175
Expenses	103,679
Revenues	139
Stockholders Equity	117,124
Net Income	-101,944
Comprehensive Net Income	-102,153
BaseVar	188,653
ECR before LimitedLiability	113%
Economic Capital Ratio	240%